Ikapharmindo Putramas Tbk PT

Ikapharmindo Putramas Tbk PT has a debt-to-equity ratio of 0.61, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.58, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not in excess. However, the company's operating cash flow is negative at -16.7 billion IDR, which raises concerns about its ability to generate cash from operations to service its debt and fund ongoing operations.

In terms of profitability, the company's return on equity (ROE) is 0.56%, and its return on assets (ROA) is 0.3%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. These figures suggest that the company is not generating significant returns relative to its equity and asset base, which could be a concern for investors. Gross profit margin stands at 42.7%, which is in line with industry norms, but the operating margin of 5.0% is relatively low, indicating that the company is facing pressure on its operating expenses.

The company's revenue is concentrated in a single business segment, as disclosed in its latest financial report, with no material geographic diversification beyond Indonesia. This lack of diversification increases its exposure to local economic and regulatory risks, which could impact its revenue stability. The company does not report revenue by geographic region, but its operations are primarily based in Indonesia, and it serves the domestic market.

Looking ahead, the company's revenue is expected to grow, but the exact rate is not specified in the available data. The company's capital expenditure of -832 million IDR suggests that it is not currently investing heavily in new projects or infrastructure, which may limit its long-term growth potential. The company's net income of 1.38 billion IDR is relatively modest compared to its revenue, indicating that it is not highly profitable on a net basis.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt highlights the company's liquidity constraints, which could become more pronounced if operating cash flow does not improve. The company's dilution risk is low, as there is no indication of significant share issuance or dilution potential in the near term.

Recent events, as disclosed in the latest financial report, include a continued focus on cost management and operational efficiency. The company has not announced any major strategic initiatives or acquisitions in the recent period, and its financial disclosures do not indicate any significant legal or regulatory issues.

The company maintains a debt-to-equity ratio of 0.61, which is significantly lower than the pharmaceutical cohort median of 0.18.

Capital expenditure relative to revenue is above the 75th percentile of the pharmaceutical cohort, indicating efficient capital usage.

Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value from share issuance.

Gross profit remains substantial at 149.4 billion IDR in the latest period, providing a base for potential margin recovery.

Long-term debt has decreased from 170.9 billion IDR in FY-1 to 170.9 billion IDR in FY0, showing slight deleveraging.

The company faces high credit risk, indicating significant concerns regarding its ability to meet financial obligations.